Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 Now Available; Delivers 300-Page Deal Directory Covering 1,107 Companies and Contract-Level Financial Terms Since 2019
Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026" has been added to ResearchAndMarkets.com's offering.
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026, a 300-page report from CurrentPartnering provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry.
Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, giving business development, licensing, and corporate strategy professionals a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.
Deal Data Paired With Real Contract Access
Each deal record in the report includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.
By reviewing actual asset purchase contracts, the report allows users to evaluate key transaction provisions including asset ownership and transfer rights, financial payment structures, intellectual property rights and technology transfer provisions, commercialization and development obligations, royalty structures, and contract duration and termination provisions, detail rarely disclosed in press releases or traditional deal databases.
Report Scope
The report profiles the top 25 most active asset purchase dealmakers, reviews the leading asset purchase deals by headline value, and organizes deal analysis by company, therapeutic area, technology type, and industry sector. It features 1,107 companies, including Travere Therapeutics, Nextmune, Relmada Therapeutics, MTD, Mucokinetica, Vivos Therapeutics, NEC OncoImmunity, and Molecular Assemblies, among many others.
The report tracks asset purchase dealmaking trends by year, phase of development, industry sector, therapy area, technology type, and most active company, alongside a comprehensive deal directory covering asset purchase transactions announced since 2019. Deal data is sourced from the publisher's proprietary deals and alliances database, updated daily from press releases, company filings, investor presentations, and SEC filings, with sources identified to allow for user verification. All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Key Benefits
Why This Report Matters
Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios. By combining comprehensive deal data, financial benchmarking, and access to real contract documents, the report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/our5r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.